Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 15/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | SCD | O00767 | 1/20 | 0.42 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3602942 | 0.87 | MEN1 (0.51) | SMN1; SMN2NAMPTSCDSCD5ESR2 | |
| SCHEMBL3599020 | 0.85 | SMN1; SMN2 (0.57) | SMN1; SMN2NAMPTSCDSCD5ESR2 | |
| SCHEMBL3601198 | 0.84 | ESR2 (0.46) | PTGER1SMN1; SMN2NAMPTSCDSCD5 | |
| SCHEMBL3599343 | 0.84 | ESR2 (0.46) | SMN1; SMN2NAMPTSCDSCD5ESR2 | |
| SCHEMBL4090882 | 0.83 | PTGER1 (0.77) | PTGER1 | |
| SCHEMBL3615745 | 0.83 | SCD (0.51) | SMN1; SMN2NAMPTSCDSCD5ESR2 | |
| SCHEMBL3601224 | 0.83 | SCD5 (0.51) | SMN1; SMN2NAMPTSCDSCD5ESR2 | |
| SCHEMBL13504968 | 0.83 | PTGER1 (0.69) | PTGER1SMN1; SMN2 | |
| SCHEMBL3605404 | 0.82 | NAMPT (0.63) | SMN1; SMN2NAMPTSCDSCD5ESR2 | |
| SCHEMBL3058098 | 0.82 | PTGER1 (0.65) | PTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041696-A1 | Compounds | SMITHKLINE BEECHAM CORPORATION | 2010-02-18 | — | — | US | disclosed |
| US-20100041696-A1 | Compounds | SMITHKLINE BEECHAM CORPORATION | 2010-02-18 | — | — | US | disclosed |
| US-20100041696-A1 | Compounds | SMITHKLINE BEECHAM CORPORATION | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041696-A1 | Compounds | CYP11B2, SCD, CYP3A5 | PTGER1 727/4885SMN1; SMN2 618/4885NAMPT 869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.